drugset / Trial / NCT04714593
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia
Phase 1/2
Unknown
24 enrolled
Shanxi Province Cancer Hospital
Shanghai Ultra-T Immune Therapeutics Co. LTD · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-CD22 CAR-T cells for the treatment of acute B lymphocytic leukemia.
Timeline
- Start
- 2021-01-15
- Primary completion
- 2021-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19-CD22 CAR-T cells | Cell therapy | 0.5 cells/kg | Intravenous |
| Subject | CD19-CD22 CAR-T cells | Cell therapy | 2 cells/kg | Intravenous |
| Subject | CD19-CD22 CAR-T cells | Cell therapy | 5 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fluorine dara marina | Unknown | 30 mg/m2 | — |